NEW JERSEY DRUG UTILIZATION REVIEW BOARD
QUAKERBRIDGE PLAZA, BUILDING 7, Rooms 200 ABC

April 23, 2014

http://www.state.nj.us/humanservices/dmahs/boards/durb/

AGENDA

I. Call to order in accordance with New Jersey Open Public Meeting Act

II. Roll Call

III. Review of draft meeting summary for January 29, 2013 meeting (pages 3-8; Tab 1)

IV. Secretary’s report (page 9; Tab 2)

V. Old Business
   A. Updated educational newsletter for Acute Pain Treatment Options (pages 11-12; Tab 3)
   B. HMO response to DURB follow-up questions regarding protocols (pages 13-15; Tab 4)

VI. New Business
   A. Protocols review (pages 17-27; Tab 5)
      1. Ranolazine (Ranexa®)
      2. Inhalation corticosteroid/Long-acting beta agonists combination
         (Advair®/Dulera®/Symbicort®)
      3. Low Molecular Weight Heparin (LMWH) – enoxaparin (Lovenox®)

VII. Informational Highlights/Reports
    2. Summary of DURB Recommendations (pages 31-32; Tab 7)
    3. DHS and DHSS Programs Top Drugs Report (pages 33-40; Tab 8)
    4. Medication information: (pages 41-44; Tab 9)
       (a) FDA: Testosterone Drugs May Increase CV, Death Risk
       (b) FDA approval of Zohydro®
       (c) Senate Finance Committee Urges CMS to Preserve Mental Health Drug Access
          (Dr. Gochfeld)